• NYX-330 designed as small molecule, oral PCSK9 inhibitor
• Passes initial critical pre-clinical tests of effectiveness
• Intended for use in combination with statin drugs to achieve substantial falls in blood LDL cholesterol levels
• Potential to have a significant impact on the incidence of cardiovascular disease.
Sydney, 27 August 2018: Noxopharm (ASX:NOX) today announces that its majority- owned US subsidiary, Nyrada (the ‘Company’), has made important progress in the development of its cholesterol-lowering drug candidate, NYX-330, with a number of key STOP-GO milestones being passed successfully. The Company believes that passing those milestones goes a long way to confirming the breakthrough potential of NYX-330.
For further information please download PDF attached:
Download this document
